Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

Sham Mailankody, Esther Mena, Constance M. Yuan, Arun Balakumaran, W. Michael Kuehl, Ola Landgren

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Multiple myeloma (MM) is a malignant plasma cell dyscrasia localized in the bone marrow. Recent studies have shown that MM is preceded in virtually all cases by a premalignant state called monoclonal gammopathy of undetermined significance (MGUS). This review focuses on non-IgM MGUS and its progression to MM. Although certain clinical markers of MGUS progression have been identified, it currently is not possible to accurately determine individual risk of progression. This review focuses on the various biologic and molecular markers that could be used to determine the risk of MM progression. A better understanding of the pathogenesis will allow us to define the biological high-risk precursor disease and, ultimately, to develop early intervention strategies designed to delay and prevent full-blown MM.

Original languageEnglish (US)
Pages (from-to)2159-2170
Number of pages12
JournalLeukemia and Lymphoma
Volume51
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Keywords

  • MGUS
  • molecular imaging
  • molecular profiling
  • Myeloma
  • prognosis
  • smoldering myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma'. Together they form a unique fingerprint.

Cite this